American Shared Hospital Services Sees Revenue Rise Amid Increased Losses in Q1 2025

Company Overview
American Shared Hospital Services (NYSE: AMS) specializes in advanced radiation therapy equipment and services. Its operations include providing Gamma Knife systems and proton beam radiation therapy (PBRT) services to medical centers in the U.S. and internationally.

First Quarter 2025 Financial Highlights
- **Total Revenues**: Increased by $896,000 to $6,112,000 from $5,216,000 year-over-year.
- **Leasing Revenues**: Decreased by $1,262,000 to $2,991,000; driven by reduced Gamma Knife volumes due to contract expirations.
- **Direct Patient Services Revenues**: Increased significantly by $2,158,000 to $3,121,000, supported by operations from acquired facilities in Rhode Island and new operations in Puebla, Mexico.
- **Total Costs of Revenue**: Increased by $2,097,000 to $5,170,000, primarily due to operational costs from newly acquired facilities.
- **Net Loss**: Increased by $744,000, totaling $625,000 or $0.10 per share compared to a profit of $119,000, or $0.02 per share in the previous year.

Positive Aspects of the Income Statement
- Significant growth in direct patient services revenue indicates strong demand and successful expansion efforts.
- Increased operating cash flows of $2,503,000 showcase improved operational efficiency despite overall losses.

Negative Aspects of the Income Statement
- Decrease in leasing revenue signifies challenges in maintaining existing contracts and achieving expected procedure volumes.
- Rising costs, particularly in other direct operating costs associated with new facilities, contributed to increased losses.

Key Statistics
- **Loss Before Income Taxes**: $(1,235,000)
- **Income Tax Benefit**: $(323,000)
- **Gross Margin**: $942,000, down from $2,143,000 year-over-year.
- **Weighted Average Common Shares**: 6,572,000 for basic and diluted calculations.
- **Total Assets**: $63,311,000 as of March 31, 2025, an increase from $60,197,000 at year-end 2024.
- **Total Liabilities**: $34,099,000, up from $30,170,000 at year-end 2024.
- **Common Stock Outstanding**: 6,450,000 as of March 31, 2025, slightly increased from 6,420,000 at year-end.

Outlook
The Company remains focused on expanding its patient service offerings, albeit facing challenges in its leasing segment. Continuous evaluation of operations and further strategic acquisitions may provide avenues for future growth and profitability.